RPHM Reneo Pharmaceuticals Inc

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences.

Jefferies London Healthcare Conference Date: Tuesday, November 14 – Thursday, November 16, 2023 Location: The Waldorf Hilton, London, UK

Piper Sandler & Co. Annual Healthcare Conference Date: Tuesday, November 28 – Thursday, November 30, 2023Location: The Lotte New York Palace, New York, NY

Links to the presentations and webcast will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.

About Reneo PharmaceuticalsReneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.

Contacts:

Danielle Spangler Investor Relations Reneo Pharmaceuticals, Inc. dspangler@reneopharma.com

Matthew Purcell, Pharm.D.Media Inquiries Russo Partners, LLC matthew.purcell@russopartnersllc.com